Back to Agenda
Unlock the Potential of Emergent Cell Therapies
Session Chair(s)
Gavin Outteridge, MA
Managing Director
AESARA Europe, United Kingdom
Allogeneic cell therapies create new opportunities for cancer care, with faster treatment and lower total cost of care than autologous therapies; this panel will explore how to enable these advances from patient, HTA and industry perspectives.
Learning Objective : Attendees will assess the value of the opportunities presented by next-wave allogeneic cell therapies in cancer treatment, from the diverse perspectives of patients, HTA bodies and the innovative pharma industry.
Speaker(s)
Innovative Pharma Perspective
Lung-I Cheng
Takeda Oncology, United States
Global Value & Access Lead, Cell Therapies
HTA and Payer Expectations of the Value Expected from Next Generation Cell Therapies
Anne D'Andon
Haute Autorité De Santé (HAS), France
Head of Medicines Assessment
The Patient Value of New Cell Therapies
Zack Pemberton-Whiteley, LLM
Leukaemia Care, United Kingdom
Chief Executive Officer
Have an account?